NASDAQ: AMRX

Amneal Pharmaceuticals (AMRX) Stock Analysis & Forecast

Nov 13 close

$21.38−0.32 (−1.5%)

Gekko Brief

AI summaryNov 9 close

Amneal Pharmaceuticals rose this week after third-quarter 2026 results topped estimates, with net revenue up 10% to $863 million and adjusted EBITDA up 30% to $207 million. Adjusted EPS came in at $0.26 against a $0.24 estimate, with earnings of $0.17 per share a year ago cited for comparison, as growth in Affordable Medicines and Specialty products offset an expected decline at AvKARE. The company also raised its full-year 2026 guidance following the beat.

Shares closed at $21.28, up 5.7%, sitting above both the 50-day average of $19.41 and the 200-day average of $15.95, with the 50-day above the 200-day. The stock trades near its 52-week high of $21.68, well above its 52-week low of $11.29. The GekkoIndex reads 52.9, placing it in the Neutral zone, and the price sits 12.7% above the Gekko Fair Value of $18.88.

The next earnings date falls on 26 February 2027, 108 days out and beyond a typical 20-trading-day hold. No insider, Congress, or unusual options activity appears in their respective windows. All six covering analysts carry a buy rating, with a consensus target of $23.43 implying 10.1% upside from current levels. Seasonality over the next 20 trading days has averaged -1% across 5 years, rising in 4 of them, a mixed historical pattern worth noting alongside the stock's recent strength relative to its moving averages.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Amneal Pharmaceuticals price vs fair value

$21.38$18.79Nov ’25May ’26Nov ’26
Close $21.38200-day averageGekko Fair Value $18.79

Amneal Pharmaceuticals quick facts

Market cap
$7.45B
P/E ratio
54.3
Forward P/E
18.6
EPS, TTM
$0.40
Revenue, TTM
$3.20B
Profit margin
4.2%
Dividend yield
—
Beta
1.21
Volume
1.72M avg 3.81M
1-year return
+79.7%
Typical daily move
±4.1%
Typical 20-day move
±8.3%
50-day average
$19.71
200-day average
$16.10
Next earnings
Feb 26 before open
Shares outstanding
348.4M
52-week range
$11.39$22.07

Amneal Pharmaceuticals swing-trade checklist

Amneal Pharmaceuticals scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive2 mixed1 headwind

  • Trendsupportive

    Above 50 and 200-day

    Close $21.38 is above the 50-day ($19.71) and 200-day ($16.10) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    51.4, Neutral

    Reading 51.4 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    13.8% above

    Price is 13.8% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 103 days

    Next report Feb 26, 2027, 103 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitymixed

    −4.1% on average

    From this point in the calendar, the next 20 trading days averaged −4.1% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Amneal Pharmaceuticals stock chart and price history

Amneal Pharmaceuticals closed at $21.38 on Nov 13, 2026, +79.7% over the past year, inside a 52-week range of $11.39 to $22.07.

Close50-day average200-day averageVolume
Amneal Pharmaceuticals share price, past year, with 50-day and 200-day moving averages and volume$10$15$20DecJan 2026FebMarAprMayJunJulAugSepOctNov21.38

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+11.1%
3 months
+16.1%
6 months
+79.2%
1 year
+79.7%
The full AMRX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open AMRX in Gekko

Follow Amneal Pharmaceuticals through every session

Put AMRX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track AMRX in GekkoFree for 7 days. No credit card required.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals develops, licenses, manufactures, markets and distributes both generic and branded medicines across many delivery forms, addressing a wide range of treatment needs. It works with dosage types such as tablets, injectables, eye drops, liquids, topical treatments, softgels, inhalants and patches, and its branded lineup includes Emverm for parasitic infections, Rytary for Parkinson's disease, and Unithroid for hypothyroidism.

The business runs through three segments. Generics covers the creation and sale of complex drug formulations. Specialty focuses on developing and marketing proprietary branded medicines, with emphasis on neurological, endocrine and parasitic conditions. AvKARE supplies pharmaceuticals and medical and surgical goods to government bodies, notably the Department of Defense and the Department of Veterans Affairs, and also handles bulk packaging and distribution of medicines and supplements under the AvKARE and AvPAK names for retail and institutional buyers. Products move through wholesalers, distributors, hospitals, pharmacy chains and independent drugstores, with activity spanning the United States, India, Ireland and other markets.

Amneal traces back to 2002, when it was set up as Atlas Holdings, Inc., taking its current name in 2018. The company is headquartered in Bridgewater, New Jersey, and its shares are listed on the NASDAQ under the ticker AMRX.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
amneal.com

Amneal Pharmaceuticals GekkoIndex: the smart money zone

Amneal Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51.4, in the Neutral zone, down 6.8 points over five sessions.

010051.4Neutral

Down 6.8 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying12+0.6%+2.3%+6.2%+9.6%
Accumulation152+2.6%+5.3%+8.5%+13.5%
Neutral (current zone)471+0.7%+1.3%+3.2%+10.6%
Distribution65+0.5%+1.3%+2.4%+6.2%
Selling2Too few readings yet

Average AMRX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the AMRX price, zone by zone.Track AMRX in Gekko

Is Amneal Pharmaceuticals stock overvalued? Gekko Fair Value

Amneal Pharmaceuticals trades 13.8% above Gekko Fair Value of $18.79, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what Amneal Pharmaceuticals shares are worth, recalculated every trading day.

$18.79

Gekko Fair Value, Nov 14, 2026

13.8% Overvalued

At the end of Aug 2026 the price was 2.6% below the estimate.

Gekko Fair ValueShare price, month end
$19$21Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open AMRX in Gekko

Amneal Pharmaceuticals insider and Congress trading

No open-market insider purchases were filed for Amneal Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for AMRX in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every AMRX insider filing, plotted on the chart in Gekko.Open AMRX in Gekko

Congress trades last 90 days

No trades in AMRX were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for AMRX, plotted on the chart in Gekko.Open AMRX in Gekko

Buybacks

Amneal Pharmaceuticals has been buying back its own shares.

Bought back, quarter ended Sep 30, 2024
$194K
As a share of market cap
0.00%

From company filings.

Amneal Pharmaceuticals earnings: next date and track record

Amneal Pharmaceuticals reports on Feb 26, 2027, before the open (103 days away), and beat the EPS estimate in 7 of its last 8 reports.

7 of 8reports beat the EPS estimate
±3.9%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

+6.9%Nov ’24+4.5%Feb ’25−2.6%May ’25+1.1%Aug ’25+3.7%Oct ’25−5.0%Feb ’26−3.1%May ’26−4.1%Jul ’26

Last earnings call, Jul 30, 2026 AI summary

What they said
Amneal reported strong Q2 2026 results, with revenue of $796M (up 10%), adjusted EBITDA of $206M (up 12%), and adjusted EPS of $0.30 (up 20%). Management described the company as being in a transformative period driven by diversification across Affordable Medicines, Specialty brands, biosimilars (pending Kashiv acquisition), GLP-1s and complex generics including transdermals and injectables. They raised the 2026 outlook for the second time this year and highlighted continued momentum into 2027. Key growth drivers include increased demand for women's health transdermal patches (capacity being expanded), new product launches (added $45M in Q2), strong Specialty brand performance (CREXONT, UNITHROID, BREKIYA), expansion of biosimilars capability via Kashiv, and complex product launches such as lanreotide and iohexol. Management emphasized manufacturing upgrades (digitization, automation, AI), operational resiliency, and planned capacity expansion. During Q&A, management reiterated conservative inclusion of lanreotide in guidance (some revenue included) while XOLAIR is expected late in the year or into early next year (not included). They quantified iohexol as a potential $50M+ opportunity and suggested Affordable Medicines could add $1–$2 billion of revenue by 2030. They described the Kashiv acquisition as enabling 6 commercial biosimilars by next year and reiterated focus on integrating Kashiv and advancing biosimilar filings.
Guidance
Company raised its 2026 outlook (no detailed numeric guidance disclosed on the call). Management indicated they conservatively included some lanreotide contribution in 2H guidance but did not include XOLAIR for this year. They expect continued momentum through 2026 into 2027. Management expects iohexol to meaningfully contribute in 2027 and estimated Affordable Medicines could add $1–$2 billion by 2030. Kashiv integration is expected to yield 6 commercial biosimilars (ALYMSYS, RELEUKO, FYLNETRA, Prolia, XGEVA, XOLAIR) commercialized by next year; they aim to file 3–4 biosimilars per year going forward.
Risks flagged
Operational risk from localized flooding at Gujarat manufacturing site (limited impact expected; operations to resume in weeks). Regulatory/timing risk for product approvals (lanreotide, XOLAIR) — management is optimistic but conservative in modeling. Market/policy risk from potential tariffs announced by administration (company awaiting details and will collaborate). Segment-specific headwinds: AvKARE revenue down 4% due to distribution mix and low-margin business. Supply chain and manufacturing complexity for products like lanreotide and iohexol create execution risk. Competitive risk/timing for biosimilar launches and potential spillover of approvals into next fiscal period.
ReportedEPSSurpriseRevenueSurpriseMove
Jul 30, 2026$0.27
est $0.24
+12.5%$796.2M
est $768.2M
+3.6%−4.1%
May 7, 2026$0.27
est $0.19
+39.0%$722.5M
est $719.7M
+0.4%−3.1%
Feb 27, 2026$0.21
est $0.18
+16.7%$814.3M
est $807.4M
+0.9%−5.0%
Oct 30, 2025$0.17
est $0.13
+30.8%$784.5M
est $806.1M
−2.7%+3.7%
Aug 5, 2025$0.25
est $0.18
+38.9%$724.5M
est $768.6M
−5.7%+1.1%
May 2, 2025$0.21
est $0.15
+40.0%$695.4M
est $744.2M
−6.6%−2.6%
Feb 28, 2025$0.12
est $0.15
−20.0%$730.5M
est $723.1M
+1.0%+4.5%
Nov 8, 2024$0.16
est $0.13
+23.1%$702.5M
est $700.8M
+0.2%+6.9%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Amneal Pharmaceuticals stock forecast and analyst price targets

Analysts’ average 12-month price target for Amneal Pharmaceuticals is $24.29, +13.6% from the last close, from 6 firms rating the stock in the last 90 days.

$24.29consensus 12-month target, +13.6% from the last close
Low $20High $28
Buy6
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 6 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 6UBSBuy, maintained$28+31.0%
Nov 5Leerink PartnersBuy, maintained$25+16.9%
Nov 4J.P. MorganBuy, maintained$25+16.9%
Nov 3OppenheimerBuy, maintained$27+26.3%
Oct 29Goldman SachsBuy, maintained$24+12.3%
+3.2%average 20-day move after past Neutral readings
−4.1%average move over the next 20 trading days in the last 5 years
±4.1%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Amneal Pharmaceuticals seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Amneal Pharmaceuticals averaged −4.1% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−23.4%2021+5.1%2022+3.1%2023−13.0%2024+7.0%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−4.6%1 of 5
Next 10 trading days−3.1%2 of 5
Next 15 trading days−3.8%2 of 5
Next 20 trading days−4.1%3 of 5
Next 30 trading days+1.9%2 of 5

For scale, AMRX’s typical 20-trading-day move in either direction is about 8.3%.

Amneal Pharmaceuticals market cap and key statistics

Amneal Pharmaceuticals’s market cap is $7.45B, with a P/E ratio of 54.3 and revenue of $3.20B over the last twelve months.

Valuation

Market cap
$7.45B
P/E ratio
54.3
Forward P/E
18.6
EPS, TTM
$0.40
Gekko Fair Value
$18.79

Trading

Volume
1.72M
Avg volume, 20 days
3.81M
52-week high
$22.07
52-week low
$11.39
Shares outstanding
348.4M

Financials

Revenue, TTM
$3.20B
Profit margin
4.2%
Return on equity
70%
Quarterly earnings growth, YoY
+157.1%

Risk and income

Beta
1.21
Typical daily move
±4.1%
Typical 20-day move
±8.3%

Amneal Pharmaceuticals stock news this week

3 headlines about Amneal Pharmaceuticals from the past week, newest first, each linking to the publisher.

Amneal Pharmaceuticals peers

Amneal Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Amneal Pharmaceuticals stock FAQ

What is Amneal Pharmaceuticals’s market cap?

Amneal Pharmaceuticals’s market cap is $7.45B at the Nov 13, 2026 close of $21.38, with 348.4M shares outstanding. The shares trade on a P/E ratio of 54.3.

What is the Amneal Pharmaceuticals stock forecast?

The consensus analyst 12-month price target for Amneal Pharmaceuticals is $24.29, +13.6% from the last close. Of the 6 firms that rated the stock in the last 90 days, 6 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Amneal Pharmaceuticals stock overvalued or undervalued?

On Gekko’s estimate Amneal Pharmaceuticals is overvalued: the Nov 13, 2026 close of $21.38 is 13.8% above Gekko Fair Value of $18.79. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Amneal Pharmaceuticals report earnings next?

Amneal Pharmaceuticals is expected to report on Feb 26, 2027, before the market opens (103 days away). Analysts expect earnings of $0.24 per share on revenue of $838.2M. Amneal Pharmaceuticals beat the earnings estimate in 7 of its last 8 reports, moving 3.9% on average across the report.

What is Amneal Pharmaceuticals’s 52-week high and low?

Amneal Pharmaceuticals’s 52-week high is $22.07 and its 52-week low is $11.39; it closed at $21.38 on Nov 13, 2026, +79.7% over the past year.

Is Amneal Pharmaceuticals stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and seasonality) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Amneal Pharmaceuticals the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.